Summit Therapeutics Inc.

Summit Therapeutics Inc.

SMMT · Nasdaq

Summit Therapeutics Inc. (SMMT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Summit Therapeutics Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-0.29

Revenue estimate

71.4K

Past earnings

12 Aug 2026
EPS actual
—
estimate -0.27
Revenue actual
—
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
23 Jul 2026
EPS actual
-0.28 (-2.0%)
estimate -0.27
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
—
estimate -0.27
Revenue actual
—
estimate 54.4K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
30 Apr 2026
EPS actual
-0.24 (+10.9%)
estimate -0.27
Revenue actual
0 (-100.0%)
estimate 54.4K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
23 Feb 2026
EPS actual
-0.29 (-274.4%)
estimate -0.08
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Summit Therapeutics missed consensus estimates in its latest earnings report, with EPS of USD -0.28 versus an estimate of USD -0.2744, and revenue of USD 0 met estimates of USD 0. In the prior quarter, EPS came in ahead of expectations while revenue fell short, with revenue missing estimates by 100.0%.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Robert W. Duggan
Employees
159
IPO date
05 Mar 2015
ISIN
US86627T1088
Website
summittxinc.com

Frequently asked questions

When does Summit Therapeutics Inc. (SMMT) next report earnings?

Summit Therapeutics Inc. (SMMT) is scheduled to report earnings on November 11, 2026.

What was Summit Therapeutics Inc.'s most recent earnings date?

Summit Therapeutics Inc. (SMMT) last reported earnings on August 12, 2026.

Where is Summit Therapeutics Inc. stock listed?

Summit Therapeutics Inc. (SMMT) is listed on Nasdaq.